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Editorial
Hypoxia-mediated radiation and chemo-sensitizing
drugs
Radiation sensitizers of one kind or another have been around for a long time. How
successful are they? What are the clinical situations where they can be used with
benefit? Which, if any, of the various classes of sensitizing agents offers the best
prospects for general exploitation in clinical radiotherapy? These and other questions
become more relevant as applications ofradiotherapy in clinical oncology expand.
Radiotherapy is used radically with curative intent as well as for palliation. In some
sites, local cure by radiation treatment is highly successful and while radical radio-
therapy does not usually address problems associated with disseminated disease, its use
in a combine modality setting is vital in a wide variety of clinical situations.
Nevertheless local failure is still a problem in some sites and clinical situations.
Suit (1982) has concluded from an analysis of survival data for a broad spectrum of
cancer patients treated with radical radiotherapy, that reduction of the incidence of
local failure would have a significant impact on long term survival. Obviously, the
magnitude of this will vary considerably with tumour type and anatomical site but the
message is clear. Eliminate radioresistance and the cure rate for some tumours should
improve.
Apparent tumour radioresistance can arise from a variety of causes. The proximity to
the tumour ofparticularly radiosensitive normal tissues such as gut, spinal cord, kidney,
etc., can limit the maximum tolerated dose to such an extent that eradication of all
clonogenic tumour cells is not achievable. The presence of occult disease that has
infiltrated into regions outside the treatment volume can confer apparent radio-
resistance. Inherent radioresistance can be due to cellular factors: for example clonogenic
cells that are temporarily out of cycle are less sensitive to radiation. However
physiological abnormalities in tumour tissue can also confer radioresistance and it is in
this context that we have a clue to an important cause of local treatment failure -
oxygen insufficiency.
Virtually all cells, be they bacterial, plant or mammalian, are relatively radioresistant
in the hypoxic state. The classical work of Thomlinson and Gray (1955) showed that in
experimental rodent tumours, necrosis often develops about 150-200 microns from the
nearest blood capillary due partly to the consumption of oxygen by cellular respiration.
The essence of their argument remains. Dormant hypoxic tumour cells located near the
oxygen diffusion limit are radioresistant but could still be capable of eventual division if
the oxygen supply were to be restored. Following fractionated radiation treatment,
oxygen respiration would decrease due to the elimination of the more sensitive oxic
cells. Surviving hypoxic cells would re-oxygenate, enter cycle and eventually provide a
focus for tumour regrowth.
There is much evidence, however, that reoxygenation can occur during a course of
treatment which reduces the numbers of hypoxic cells and is therefore beneficial. This is
one of the contributory factors to the superior efficacy of multi-fraction treatments.
However, it is the hypoxic cells that remain after treatment is completed that are a
source of tumour regrowth. Most solid tumours, human as well as experimental, exhibit
some necrosis quite early in their development and even in apparently well-vascularised
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regions of tumours, micro necrotic foci are often observed in histological preparations.
There is no doubt that hypoxia is the major influence on radiation response of most
experimental solid tumours treated with single doses of radiation. There is equally no
doubt, however, that in these experimental systems, re-oxygenation during fractionated
treatment reduces, and in some cases eliminates, the burden of hypoxic cell resistance.
Re-oxygenation must be an important factor in the response of human tumours to
radiation. The vexing question though remains: To what extent does re-oxygenation
reduce the number of hypoxic cells and in which tumours is residual hypoxia a cause of
treatment failure? Some clinical trials of radiotherapy of haemoglobin status (Hank &
Smith, 1977; Bush et al., 1978; Dische et al., 1983) indicate that hypoxia certainly can
be a factor in the response of some cancers of the cervix and the head and neck region.
The problem, however, that bedevils such clinical trials is the means of identifying those
tumours where hypoxia-cell resistance is an important factor in overall response and
those where it is not. This problem is relevant, of course, to the current trials of
chemical sensitizers for hypoxic cells.
Chemical radiosensitizers
Interest in the ubiquity of the oxygen effect that developed in the late fifties and early
sixties prompted the development of chemical agents that would "mimic" the oxygen
effect. There are now many examples of such agents showing a wide diversity of
chemical structure. With very few exceptions, sensitization occurs only in hypoxia and
this remains the main rationale for differential radiosensitization, i.e. enhanced tumour
response without a concomitant increase in normal tissue radiation morbidity.
While most in vitro chemical radiosensitizers, for one reason or another, show little if
any sensitization in vivo, the nitroheterocycles are an exception, particularly the
nitroimidazoles. Many compounds of this class show good tumour penetration due
mainly to their favourable pharmacokinetic properties but their toxicological properties
vary widely.
The drug Metronidazole or "flagyl" was investigated clinically as a radiosensitizer in
the early seventies. While the drug is a modest sensitizer on a weight-for-weight basis, it
was the first hypoxic cell sensitizer shown to be effective in experimental solid tumours.
However, clinical studies soon showed that maximum tolerated doses were insufficient
for substantial radiosensitization in human tumours.
By this time, it was well-established that the efficacy of radiosensitizers of this type
was directly related to the oxidative or "electron-affinic" properties of the compounds.
This led to the proposal that structural modifications of the nitroimidazole nucleus
involving the transposition of the nitro group from the 5- to the 2-position in the ring
should greatly increase the potency. This was confirmed for a range of such com-
pounds. One drug, misonidazole showed much promise in that in almost all experi-
mental tumour systems, large sensitization factors were observed.
Preliminary clinical studies showed good tumour penetration accompanied by some
evidence of radiosensitization and randomized clinical trials were initiated, most of
which are now complete. Overall, however, the results have been disappointing
(collected papers). Evidence of early benefit was noted in some of these trials but much
of this has been lost during extensive follow-up. The major problem has proved to be
the neurological complications encountered with this drug which have prevented its use
at dosages sufficient to give large sensitization factors. It may well be that many of the
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only a fraction of the patients involved had tumours where residual hypoxia was a
cause of treatment failure.
In specialised circumstances, the problem of insufficient dosage has been overcome by
ingenious techniques for local administration (collected papers) and these studies are
yielding encouraging results. Further, recent analysis of results from an MRC trial of
hyperbaric oxygen in the radiotherapy of advanced carcinoma of the cervix has
provided further evidence concerning the influence of chronic anaemia in the develop-
ment and location of tumour hypoxia (Dische et al., 1983). This may have an impact
on the identification of patient sub-groups that would benefit in future trials of
radiosensitizers.
New sensitizers
Recent developments of new sensitizing drugs have been influenced by several factors.
The neurotoxic properties of sensitizers of the misonidazole type are directly related to
the lipophilic properties of the compounds and this has partly guided the development
of less toxic drugs.
Two drugs currently in clinical trial are the misonidazole analogue SR 2508
developed as a radiosensitizer at the Stanford Research Institute and the Roche
Compound Ro 032-8799.
SR 2508 is less lipophilic than misonidazole and, as expected, has proved to be much
less neurotoxic in experimental animals. Phase I and II studies are in progress in the
USA (collected papers) and there is clear evidence of better tumour penetration and
more favourable tumour/plasma ratios than are obtainable with misonidazole. Further,
substantially higher doses can be administered without encountering neurological
complications. SR 2508 may prove to be near the optimum compound with respect to
the lipophilicity relationship. Although the fall-off of penetration with decreasing
lipophilicity occurs in tumours at substantially lower values than for neural tissue,
compounds with octanol-water partition coefficients not much lower than SR 2508 tend
to show decreased efficiencies of tumour uptake (Brown & Workman, 1980).
The compound Ro 03-8799 also appears to be less toxic than misonidazole and
somewhat more effective in experimental tumour systems. Usually, higher drug levels
are found in these model tumours compared with those in normal tissues and results
from Phase I clinical trials now in progress show that this is the case in human tumours
also (collected papors). The lipophilicity of this drug is highly pH-dependent due to the
acid-base characteristics of the side chain substituent. The higher acidity of the extra-
cellular fluid in hypoxic tissues may be a factor responsible therefore for the more
favourable tumour uptake.
The search for new and more potent sensitizers is underpinned, as it must be, by the
study of mechanisms. Oxygen itself acts as a radiation modifier by two distinct free
radical mechanisms and there is evidence that is also true for sensitizers of the
misonidazole type. Recently, however, mechanistic studies have tended to concentrate
on methods of "biochemical manipulation" of the cell.
The compound buthionine sulphoximine (BSO) is an inhibitor of glutathione
synthesis in mammalian cells due to its suppression of the y glutamyl cysteine
synthetase step in biosynthesis chain. Sensitization due to misonidazole or its analogues
is enhanced when this inhibitor is administered prior to irradiation either in vitro or in
vivo. Similar enhanced sensitization can also be achieved by the administration of agents
which react directly with intracellular glutathione.
The origin of this enhanced sensitization almost certainly involves the inhibition of288 EDITORIAL
intracellular repair processes. Such inhibition could be exploited in a clinical sense
provided there was a basis for a true differential effect. Repair inhibition in tumour
cells is demonstrable and it is encouraging that the enhanced sensitization efficiency of
electron-affinic sensitizers by SH-suppressive agents appears to be dependent to some
extent on reduced oxygenation. It is too early though to speculate whether or not this
approach will have any clinical application.
Some promise for the development of more potent sensitizers lies in observations that
some compounds of the electron-affinic type are much more efficient than would be
predicted from their redox properties. Examples of these are the "mixed function"
compounds. The sensitizer RSU 1069 and its derivatives are nitroimidazoles containing
a monofunctional alkylating group in the side chain. Some of these compounds are
more efficient than misonidazole by at least an order of magnitude both in vitro and in
vivo (Adams et al., 1984). A contributory factor in this is the DNA reactivity which
may be a mechanism of localisation of the sensitizer. It is well-established that
enhancement of radiation damage in DNA is a major mechanism of sensitization by
oxygen and other electron-affinic sensitizers.
Chemosensitization
Evidence for the resistance of hypoxic tumour cells to radiation raises the question: Are
hypoxic cells relatively resistant to the cytotoxic action of some anti-cancer drugs? The
answer is probably yes. Hypoxic cells in tumours are located in poorly-vascularised
regions and drug access may be limited. Further, oxygen is likely to be required for a
cytotoxic response to some chemotherapeutic drugs particularly if energy-dependent
processes are involved in the mechanisms of action. There are various reports that
mammalian cells in vitro are less sensitive to the action of various anti-cancer drugs
including some anthracyclines and anti-metabolites.
Some drugs of the nitroimidazole class are unusual in that they are much more
cytotoxic under hypoxic conditions. Metronidazole, for example, is used routinely as an
antibiotic for various anaerobic infections and other nitroimidazoles have found
application in the treatment of some parasitic infections where there is an anaerobic
vector in the mechanism. These agents are also differentially cytotoxic to hypoxic
mammalian cells and this has prompted their investigation as anti-cancer agents aimed
at attacking hypoxic cells in tumours.
It has been found that treatment of tumour-bearing mice with misonidazole, or other
nitroimidazole analogues increases the response of these tumours to subsequent
treatment with some other drugs - particularly alkylating agents and nitrosoureas. The
increased anti-tumour response is not due, however, to the selective action of each drug
against the respective oxic and hypoxic sub-populations but is rather a true potentiation
phenomenon. Enhanced chemosensitivity is much greater in tumours than in normal
tissue indicating a clear basis for increased therapeutic benefit.
Various mechanisms for chemosensitization have been proposed (collected papers)
but the evidence is now compelling that a key step in the process involves a hypoxia-
dependent process. The activity of nitroimidazoles used as anaerobic antibiotics rests on
the reducibility of the nitro group. Anaerobic metabolic reduction of these compounds
also occurs in mammalian cells and there is some support for the view that a reduced
intermediate is involved in the overall chemosensitization process.
Whether or not chemosensitization will ultimately find a role in the clinic remains toEDITORIAL 289
be seen. However, the evidence that the cytotoxic activity of one drug can be enhanced
by another in a process mediated through tumour hypoxia is encouraging since it
provides a basis for a differential antitumour response.
MRC Radiobiology Unit, Harwell, G.E. Adams
Didcot, Oxon OX 1I ORD.
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